RPL23A's Role in Cellular and Biological Processes (G389101)

Target Name: RPL23AP43

NCBI ID: G389101

RPL23AP43

Other Name(s): RPL23A_16_360 | ribosomal protein L23a pseudogene 43 | Ribosomal protein L23a pseudogene 43

RPL23A's Role in Cellular and Biological Processes

RPL23A_16_360 is a gene that encodes a protein known as RPL23A, which is a key regulator of the Replication Protein Complex (RPC) in eukaryotic cells. The RPC is a complex of proteins that ensure the accurate replication of DNA in the cell, which is essential for cell growth, development, and survival. RPL23A plays a crucial role in regulating the assembly and disassembly of the RPC, as well as the processing of damaged DNA, which is a hallmark of the aging process.

Mutations in the RPL23A gene have been linked to a variety of cellular and biological processes, including the development of cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the study of RPL23A_16_360 is of great interest in the context of disease and therapeutic development.

Drug Target and Biomarker

RPL23A has been identified as a potential drug target in the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions has been attributed to its involvement in the regulation of DNA replication, cell growth, and apoptosis.

One of the potential mechanisms by which RPL23A may contribute to disease is its role in the regulation of the aging process. In aging cells, the RPC is unable to process damaged DNA efficiently, leading to an accumulation of mutations that can contribute to the development of age-related diseases, such as cancer and neurodegenerative diseases. Therefore, targeting RPL23A with drugs that can enhance its function in the RPC may be a promising strategy for the treatment of these conditions.

Another potential mechanism by which RPL23A may contribute to disease is its role in the regulation of cell growth. The RPC plays a critical role in regulating cell size and morphology, as well as cell division, which are essential for the growth and development of tissues. Therefore, alterations in the RPC can lead to the development of cancer, neurodegenerative diseases, and other diseases. Targeting RPL23A with drugs that can enhance its function in the RPC may be a promising strategy for the treatment of these conditions.

In addition to its potential therapeutic applications, RPL23A has also been identified as a potential biomarker for the assessment of disease risk. The RPL23A gene has been shown to be expressed in a variety of tissues and cells, including cancer cells, neurons, and immune cells . Therefore, the levels of RPL23A in tissues these may be used as a biomarker for the assessment of disease risk. This approach may be particularly useful for the development of personalized medicine, where the treatment regimen is tailored to the specific needs and characteristics of each individual patient.

Conclusion

RPL23A_16_360 is a gene that encodes a protein that plays a critical role in the regulation of the Replication Protein Complex in eukaryotic cells. Its function in this process is essential for the accurate replication of DNA and the regulation of cell growth and apoptosis. The study of RPL23A_16_360 is of great interest in the context of disease and therapeutic development, as its mutations have been linked to a variety of cellular and biological processes. Additionally, RPL23A has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of RPL23A in these conditions and to develop effective therapies based on this knowledge.

Protein Name: Ribosomal Protein L23a Pseudogene 43

The "RPL23AP43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets